Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A systematic review and meta-analysis
Fatimah Hassan Alshihabi, Kholoud Mohammed Alzubaidi, Salha Ali Alzubaidi, Reem Hasan Alzubaidi, Khloud Abdullah Alharbi, Ahlam Waqit Alessa, Sara Zain Alessa, Hanin Abdullah Bamahdi, Amirah Ahmed Almajdi, Khalid Ahmed AlQuzi, Omar Mohammed Alrufaydi
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder in children, characterized by recurrent abdominal pain and altered bowel habits. It is associated with impaired quality of life and school performance. Increasing evidence suggests that gut microbiota dysbiosis plays an important role in the pathophysiology of pediatric IBS, leading to growing interest in microbiome-targeted therapies such as probiotics, prebiotics, and synbiotics. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of these interventions in children and adolescents with IBS. A comprehensive search of PubMed and Google Scholar was conducted for studies published up to 2024, including randomized controlled trials (RCTs) and other controlled studies involving participants aged 1–18 years diagnosed with IBS. The primary outcome was improvement in abdominal pain severity and frequency, while secondary outcomes included changes in bowel habits, bloating, quality of life, and adverse events. Thirteen studies involving 1169 participants met the inclusion criteria, comprising ten RCTs and three controlled clinical studies. Probiotic interventions, particularly